netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Statins May Treat Dry AMD

Left: before statin treatment; right: same patient, one year after statin treatment. Photo: Harvard University

 RPB-supported researchers at Massachusetts Eye and Ear/Harvard Medical School and scientists at University of Crete have conducted a phase I/II clinical trial investigating the efficacy of statins (cholesterol-lowering medications) for the treatment of patients with the dry form of age-related macular degeneration (AMD) — the leading cause of blindness in the developed world. Although effective treatments are available for the wet form of AMD, they are currently lacking for the more prevalent dry form.

The researchers found evidence that treatment with high-dose atorvastatin (80mg) is associated with regression of lipid deposits and improvement in visual acuity, without progression to advanced disease, in high-risk AMD patients.

Read the story.

Read the study.

Related News: Feature Story, Macular Degeneration, Top Story

Reversing Retinal Degenerative Diseases: We’re One Step Closer

RPB-supported researchers made a critical discovery about the gene mutation that causes many retinal degenerative diseases, opening the door for a new line of research into potential treatments.

Read More

 

Understanding Usher Syndrome: New Findings

RPB-supported researchers make progress in characterizing the genetic components of Usher syndrome.

Read More

 

New Stem Cell Model Replicates Macular Degeneration

The model will allow researchers to better assess treatments for this hard-to-study cause of blindness.

Read More

 

Researchers ID Key Compounds Related to Blood Vessel Growth in Wet AMD

The findings may have significant therapeutic implications for AMD, the most common cause of elderly blindness in the developed world

Read More

 

FAQs: Aug. 21 Solar Eclipse

RPB provides information to help you protect your eyes during the upcoming solar eclipse.

Read More

 

RPB-supported Researchers ID Master Molecule behind Corneal Inflammation

RPB-supported researchers at the University of Illinois at Chicago have identified an enzyme present in the cornea that triggers inflammation during and even after a herpes virus infection.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.